Martin Gore
Overview
Explore the profile of Martin Gore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
13856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith H, Glen J, Turnbull N, Peach H, Board R, Payne M, et al.
Eur J Cancer
. 2020 Jun;
135:113-120.
PMID: 32563895
Introduction: Anorectal melanoma (ARM) is a rare disease with a poor prognosis. There is no consensus as to the optimal primary surgical treatment for ARM, with advocates for both radical...
2.
Powell N, Ibraheim H, Raine T, Speight R, Papa S, Brain O, et al.
Lancet Gastroenterol Hepatol
. 2020 Jun;
5(7):679-697.
PMID: 32553146
Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated...
3.
Smith H, Bagwan I, Board R, Capper S, Coupland S, Glen J, et al.
Eur J Cancer
. 2020 Jun;
135:22-30.
PMID: 32531566
Ano-uro-genital (AUG) mucosal melanomas are rare cancers associated with poor outcomes and limited evidence-based management. The United Kingdom AUG mucosal melanoma guideline development group used an evidence-based systematic approach to...
4.
Cebon J, Gore M, Thompson J, Davis I, McArthur G, Walpole E, et al.
J Immunother Cancer
. 2020 Apr;
8(1).
PMID: 32317292
Background: To compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants...
5.
OReilly A, Hughes P, Mann J, Lai Z, Teh J, Mclean E, et al.
Support Care Cancer
. 2019 May;
28(2):561-570.
PMID: 31089820
Purpose: The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with metastatic melanoma achieving high-quality durable responses. Metastatic melanoma survivors are a new population in the era of...
6.
Gore M, Hackshaw A, Brady W, Penson R, Zaino R, McCluggage W, et al.
Gynecol Oncol
. 2019 Apr;
153(3):541-548.
PMID: 31005287
Objectives: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer. Methods: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC:...
7.
McGuire W, Penson R, Gore M, Casado Herraez A, Peterson P, Shahir A, et al.
BMC Cancer
. 2018 Dec;
18(1):1292.
PMID: 30591028
Background: Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. This randomized,...
8.
Corrie P, Marshall A, Nathan P, Lorigan P, Gore M, Tahir S, et al.
Ann Oncol
. 2018 Jul;
29(8):1843-1852.
PMID: 30010756
Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma...
9.
Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez J, et al.
Cell
. 2018 Apr;
173(3):581-594.e12.
PMID: 29656895
Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across...
10.
Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al.
Cell
. 2018 Apr;
173(3):595-610.e11.
PMID: 29656894
The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective...